Cite
HARVARD Citation
Park, J. et al. (2022). Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer. American journal of clinical oncology. p. . [Online].